Form 4: MAIA Biotechnology Director Receives Stock Grant
Insider Transaction (Form 4)
Jean-Manasse Theagene, a Director of MAIA Biotechnology, Inc., received 32,012 shares of common stock on September 30, 2026.
Summary
- Grant/award: acquired 32,012 Stock Options on September 30, 2026; holds 32,012 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jean-Manasse Theagene — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Grant/award | Stock Options | 32,012 | — | — | 32,012 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Grant/award (32,012 shares) |
Keywords
insider transaction, Form 4, MAIA, MAIA Biotechnology, Inc., neutral, Jean-Manasse Theagene
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.